Previous 10 | Next 10 |
MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Off...
Summary Ocugen is developing the Indian COVID vaccine Covaxin in the US and has completed an immuno-bridging study with positive results. However, Peter Marks the head of the Center for Biologics Evaluation and Research (CBER) stated recently that in his view going forward immuno-bridgi...
Summary Ocugen is developing the Indian COVID vaccine Covaxin in the US and has completed an immuno-bridging study with positive results. However, the head of the Center for Biologics Evaluation and Research stated recently that going forward immuno-bridging studies are insufficient. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2022, I was able to greatly reduce my stock portfolio’s losses by shorting several U.S. equities. I found it fairly easy to find favorable stocks to short, as the valuations of many companies were ridiculously high l...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roman Tiraspolsky / Shutterstock.com Party City (NYSE: PRTY ) stock is in the news Monday as investors prepare for the retail company to file for bankruptcy. While there’s no official filing just ye...
Penny Stocks, News, & Market Momentum This Week This is the first full week of the New Year and one that many investors will be focused on. Not only will we see Federal Reserve Chair Jerome Powell’s first major speech of the year, but there’s also no time wasted for the firs...
Ocugen ( NASDAQ: OCGN ) added ~15% pre-market, announcing that a U.S. trial for the COVID-19 vaccine candidate the company develops with India’s Bharat Biotech reached both co-primary endpoints in a Phase 2/3 clinical trial. The randomized study involving 419 U.S. adults wa...
Study met both co-primary endpoints with robust immune responses COVAXIN ™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the United States (U.S.), with no vaccine-related serious adverse events, t...
Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) climbed as high as 14.2% on Thursday, to $1.29, shortly before noon. Ocugen focuses on gene and cell therapies and vaccines to treat retinal diseases, infectious diseases, and orthopedic conditions. The stock is a meme favorite, l...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As we enter the new year, it’s time to go through your portfolio and discover which meme stocks to sell. In many ways, I believe that 2022 can be viewed as the year of “the baby and the bathwater” for U.S...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...